Pneumococcal conjugate vaccine is effective in pediatric HSC transplant recipients
This article has no abstract so we have provided the first paragraph of the full text.
Life-threatening pneumococcal infections are common in children who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT). Vaccination with 23-valent pneumococcal polysaccharide vaccines has been shown to elicit only low response rates as a result of immunologic immaturity of the recipients. A study by Meisel et al. has shown that a heptavalent pneumococcal conjugate vaccine (7vPCV) induced protective antibody responses in children who received an alloHSCT transplant from a related or unrelated donor.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.